安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Athira Pharma
Latest News November 6, 2025 Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update September 11, 2025 Athira Pharma Announces Reverse Stock Split August 14, 2025 Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
- News – Athira Pharma
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) May 29, 2024
- Pipeline – Athira Pharma
Athira is currently conducting a first-in-human, dose escalation Phase 1 clinical trial evaluating safety, tolerability and pharmacokinetics of ATH-1105 in up to 80 healthy volunteers Athira expects to commence dosing of ALS patients in 2025
- About – Athira Pharma
At Athira, we are committed to restoring, rebuilding and retaining connections Our scientific philosophy is rooted in supporting a healthy neuronal network, improving the lives of patients and caregivers by maintaining their personal connections
- Careers – Athira Pharma
Legitimate email communications from Athira’s hiring team will always come from an email address that ends with “@athira com” or “@app bamboohr com” (our third-party applicant tracking system)
- Science – Athira Pharma
Select Athira Scientific Publications By clicking on the links below, you will access PDF reprints of peer-reviewed publications made available by scientific journals via open-access
- Therapeutic Focus – Athira Pharma
At Athira, We Are Focused on Improving Neuronal Health by Promoting Natural Repair Systems Neurodegenerative diseases — like ALS — occur when the brain is unable to build, restore, or maintain connections
- Patients – Athira Pharma
We believe Athira’s unique approach has the potential to change the treatment paradigm to restore neuronal health Athira aims to discover and develop important new therapeutics with the potential to impact a wide range of neurological diseases and conditions
|
|
|